We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
AWARENESS AND RECOMMENDATION RELATED TO DPYD TESTING AMONG MEDICAL ONCOLOGISTS IN ROMANIA: A SURVEY STUDY.
- Authors
DEAC, ANDRADA LARISA; SUR, DANIEL; GORZO, ALECSANDRA; LUNGULESCU, CRISTIAN-VIRGIL; BURZ, CLAUDIA-CRISTINA; BĂLĂCESCU, LOREDANA; DUMITRESCU, ELENA ADRIANA; STĂNCULEANU, DANA LUCIA; BUZOIANU, ANCA-DANA
- Abstract
Fluoropyrimidines are used in many types of cancers and remain one of the most prescribed chemotherapy agents despite the development of newer anti-cancer treatments. Fluoropyrimidines-related mechanism of toxicity is a well-known subject, and DPYD mutation testing is a clinical validation method to identify patients at risk or who already have severe toxicities. In this study, the aim was to evaluate the attitudes and experiences of Romanian medical oncologists regarding DPYD testing. An online survey was sent to members of the Romanian Society of Medical Oncology. 93 oncologists responded to the survey with almost 25% of the responders using fluoropyrimidines on a daily basis, mostly in gastrointestinal cancers. Adverse events (AE) were reported as average by 59% of the oncologists, with grade 2 being the most common AE in clinical practice (90%). However, despite the potential benefits of DPYD testing, 87% of the oncologists surveyed reported that they rarely or never recommended DPYD testing. The main reason for this was the lack of reimbursement from the authorities. This highlights the need for Romanian medical oncologists to consider DPYD testing in their daily clinical care, despite the lack of reimbursement and the absence of a generalized endorsement from international professional oncology societies.
- Subjects
ROMANIA; ONCOLOGISTS; GASTROINTESTINAL cancer; PROFESSIONAL associations; CLINICAL medicine; FLUOROPYRIMIDINES
- Publication
Farmacia, 2023, Vol 71, Issue 4, p841
- ISSN
0014-8237
- Publication type
Article
- DOI
10.31925/farmacia.2023.4.21